Abstract
Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 135-152 |
| Number of pages | 18 |
| Journal | Advances in Therapy |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2018 |
Fingerprint
Keywords
- Adult T-cell leukemia–lymphoma
- Chemotherapy
- Human T-cell lymphotropic virus type 1
- Oncology
- Relapsed/refractory disease
- Targeted agents
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
A Review of New Findings in Adult T-cell Leukemia–Lymphoma : A Focus on Current and Emerging Treatment Strategies. / Hermine, Olivier; Carlos Ramos, Juan; Tobinai, Kensei.
In: Advances in Therapy, Vol. 35, No. 2, 01.02.2018, p. 135-152.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - A Review of New Findings in Adult T-cell Leukemia–Lymphoma
T2 - A Focus on Current and Emerging Treatment Strategies
AU - Hermine, Olivier
AU - Carlos Ramos, Juan
AU - Tobinai, Kensei
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.
AB - Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.
KW - Adult T-cell leukemia–lymphoma
KW - Chemotherapy
KW - Human T-cell lymphotropic virus type 1
KW - Oncology
KW - Relapsed/refractory disease
KW - Targeted agents
UR - http://www.scopus.com/inward/record.url?scp=85041556246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041556246&partnerID=8YFLogxK
U2 - 10.1007/s12325-018-0658-4
DO - 10.1007/s12325-018-0658-4
M3 - Review article
C2 - 29411267
AN - SCOPUS:85041556246
VL - 35
SP - 135
EP - 152
JO - Advances in Therapy
JF - Advances in Therapy
SN - 0741-238X
IS - 2
ER -